Dietary Changes Leading to Euglycemic Diabetic Ketoacidosis in Sodium-Glucose Cotransporter-2 Inhibitor Users: A Challenge for Primary Care Physicians?
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The use of euglycemic diabetic ketoacidosis (EDKA) related to sodium-glucose cotransporter 2 in-hibitors (SGLT2i) use in people with diabetes has been increasingly reported. The causes are multifactorial, and di-etary changes in SGLT2i users were observed to trigger EDKA. A ketogenic diet or very low-carbohydrate diet (VLCD) enhances body ketosis by breaking down fats into energy sources, causing EDKA. This study aimed to un-derstand the patient specific risk factors and clinical characteristics of this cohort. Methods: Several databases were carefully analyzed to understand the patients’ symptoms, clinical profile, labora-tory results, and safety of dietary changes in SGLT2i’s. Thirteen case reports identifying 14 patients on a ketogenic diet and SGLT2i’s diagnosed with EDKA were reviewed. Results: Of the 14 patients, 12 (85%) presented with type-2 diabetes mellitus (DM) and 2 (15%) presented with type-1 DM. The duration of treatment with SGLT2i before the onset of EDKA varies from 1 to 365 days. The duration of consuming a ketogenic diet or VLCD before EDKA onset varies from 1 to 90 days, with over 90% of patients hospi-talized <4 weeks after starting the diet. At presentation, average blood glucose was 167.50±41.80 mg/dL, pH 7.10±0.10, HCO3 8.1±3.0 mmol/L, potassium 4.2±1.1 mEq/L, anion-gap 23.6±3.5 mmol/L, and the average hemo-globin A1c was 10%±2.4%. The length of hospital stay ranged from 1 to 15 days. None of the patients were reinitiated on SGLT2i’s, and 50% (2/4) of the patients reported were on the ketogenic diet or VLCD upon patient questioning.Conclusion: Despite the popularity of the ketogenic diet and VLCD for weight loss, their use in diabetics taking SGLT2i’s is associated with EDKA. Physicians should educate patients with diabetes taking SGLT2i’s about the risk of EDKA. In addition, patients should be encouraged to include their physicians in any decision related to signifi-cant changes in diet or exercise routines. Further research is needed to address if SGLT2i’s should be permanently discontinued in patients with diabetes on SGLT2i and whether the ketogenic diet developed EDKA.
Abstract
Background: The use of euglycemic diabetic ketoacidosis (EDKA) related to sodium-glucose cotransporter 2 in-hibitors (SGLT2i) use in people with diabetes has been increasingly reported. The causes are multifactorial, and di-etary changes in SGLT2i users were observed to trigger EDKA. A ketogenic diet or very low-carbohydrate diet (VLCD) enhances body ketosis by breaking down fats into energy sources, causing EDKA. This study aimed to un-derstand the patient specific risk factors and clinical characteristics of this cohort. Methods: Several databases were carefully analyzed to understand the patients’ symptoms, clinical profile, labora-tory results, and safety of dietary changes in SGLT2i’s. Thirteen case reports identifying 14 patients on a ketogenic diet and SGLT2i’s diagnosed with EDKA were reviewed. Results: Of the 14 patients, 12 (85%) presented with type-2 diabetes mellitus (DM) and 2 (15%) presented with type-1 DM. The duration of treatment with SGLT2i before the onset of EDKA varies from 1 to 365 days. The duration of consuming a ketogenic diet or VLCD before EDKA onset varies from 1 to 90 days, with over 90% of patients hospi-talized <4 weeks after starting the diet. At presentation, average blood glucose was 167.50±41.80 mg/dL, pH 7.10±0.10, HCO3 8.1±3.0 mmol/L, potassium 4.2±1.1 mEq/L, anion-gap 23.6±3.5 mmol/L, and the average hemo-globin A1c was 10%±2.4%. The length of hospital stay ranged from 1 to 15 days. None of the patients were reinitiated on SGLT2i’s, and 50% (2/4) of the patients reported were on the ketogenic diet or VLCD upon patient questioning.Conclusion: Despite the popularity of the ketogenic diet and VLCD for weight loss, their use in diabetics taking SGLT2i’s is associated with EDKA. Physicians should educate patients with diabetes taking SGLT2i’s about the risk of EDKA. In addition, patients should be encouraged to include their physicians in any decision related to signifi-cant changes in diet or exercise routines. Further research is needed to address if SGLT2i’s should be permanently discontinued in patients with diabetes on SGLT2i and whether the ketogenic diet developed EDKA.
참고문헌 (17)
- Mistry S, "Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet : a case series and review of literature", AACE Clin Case Rep, 7, pp.17~19 (2020)
- Sood M, "Euglycemic diabetic ketoacidosis with SGLT2 inhibitor use in a patient on the Atkins diet : a unique presentation of a known side effect", AACE Clin Case Rep, 4, pp.104~107 (2018)
- Garay PS, "A case of euglycemic diabetic ketoacidosis triggered by a ketogenic diet in a patient with type 2 diabetes using a sodium-glucose cotransporter 2 inhibitor", Clin Diabetes, 38, pp.204~207 (2020)
- Sinha S, "Euglycaemic ketoacidosis from an SGLT2inhibitor exacerbated by a ketogenic diet", Med J Aust, 212, pp.46~ (2020)
- Earle M, "Euglycemic diabetic ketoacidosis in concurrent very low-carbohydrate diet and sodium-glucose transporter-2inhibitor use : a case report", Clin Pract Cases Emerg Med, 4, pp.185~188 (2020)
- Latif A, "Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2inhibitor(empagliflozin)", Drug Ther Bull, 59, pp.93~95 (2021)
- Fukuyama Y, "Euglycemic diabetic ketoacidosis due to a strict low-carbohydrate diet during treatment with sodium-glucose cotransporter 2 inhibitors", Acute Med Surg, 7, pp.e480~ (2020)
- Leys LE, "Severe euglycemic diabetic ketoacidosis associated with use of canagliflozin", Am J Respir Crit Care Med, 199, pp.A1734~ (2019)
- Khan A, "Metabolic acidosis and its predisposing factor : euglycemic ketoacidosis caused by empagliflozin and low-carbohydrate ketogenic diet in type 2 diabetes mellitus : case report", SN Compr Clin Med, 2, pp.1243~1247 (2020)
- Fieger EI, "Successful reimplementation of a very low carbohydrate ketogenic diet after SGLT2 inhibitor associated euglycemic diabetic ketoacidosis", AACE Clin Case Rep, 6, pp.e330~e333 (2020)
- Tauseef A, "Sodiumglucose linked transporter inhibitors as a cause of euglycemic diabetic ketoacidosis on a background of starvation", Cureus, 12, pp.e10078~ (2020)
- Richstein R, "MON-LB124 euglycemic diabetic ketoacidosis on initiation of ertugliflozin in a patient with type 2 diabetes mellitus precipitated by a ketogenic diet", J Endocr Soc, 4(Supplement_1), pp.MON-LB124~ (2020)
- Castellanos-Diaz J, "SAT-685 euglycemic diabetic ketoacidosis in T1d : the era of SGLT-2 inhibitors and keto-diet", J Endocr Soc, 4(Supplement_1), pp.SAT-685~ (2020)
- Vallon V, "Targeting renal glucose reabsorption to treat hyperglycaemia : the pleiotropic effects of SGLT2 inhibition", Diabetologia, 60, pp.215~225 (2017)
- McGuire DK, "Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes : a meta-analysis", JAMA Cardiol, 6, pp.148~158 (2021)
- Somagutta MR, "Euglycemic diabetic ketoacidosis and sodium-glucose cotransporter-2inhibitors : a focused review of pathophysiology, risk factors, and triggers", Cureus, 13, pp.e13665~ (2021)
- Modi A, "Euglycemic diabetic ketoacidosis : a review", Curr Diabetes Rev, 13, pp.315~321 (2017)